ROSETTA CRC-203: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Bristol-Myers Squibb

Full Title
Protocol CA2660003: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Study Treatment
VEGF-A x PD-L1 bispecific antibody pumitamig in combination with standard chemotherapy vs bevacizumab in combinatino with standard chemotherapy. 

Eligibility/Info
Eligible patients must have been diagnosed with an unresectable or metastatic colorectal adenocarcinoma that has not yet been treated in the advanced/metastatic setting. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage